+34 679 490 537info@nanbiosis.com

U9. Synthesis of Nanoparticles Unit

Ciber bbn

U9. Synthesis of Nanoparticles Unit

    • Entities: Institute of Nanoscience of Aragón (INA)
    • Address: R&D Building, Campus Río Ebro, Universidad de Zaragoza. C/Mariano Esquirl S/n, 50018, Zaragoza, Spain
    • Phone: 34 976 761000 ext. 3496

Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27.

Order request

Description

This unit, integrated in the Nanostructured Films and Particles Group at the Institute of Nanoscience of Aragón (INA) coordinated by Dr. Jesús Santamaría, has as objective the synthesis of nanoparticles with applications in biomedicine. The unit provides an automated system for the synthesis of nanoparticles using laser-induced pyrolysis of chemical precursors in gas and/or aerosol phase, which enable either individual nanoparticles or biocompatible hybrid nanostructures to be produced in large quantities. In addition, this facility is able to draw on a wide range of nanoparticles fabrication technique, as well as having the necessary specialized personnel, to undertake exhaustive characterization of the microstructure, chemical composition, particles size and distribution of sizes, as well as magnetic, optical and colloidal properties and degree of biological functionality of the synthesized material.

U9. Services & Rates

Equipments

In addition to this there is immediate access to advanced electron microscopies (SEM, TEM, HRTEM, UHRTEM), as well as other surface analysis and characterization equipment (XPS, XRD, FTIR, magnetic characterization). The equipment available makes this Unit unique to produce a wide variety of nanoparticles, , inorganic, polymeric, or multifunctional hybrid nanocomposites.

Active projects

TitleFundin: OrganismCall: Funding source Role
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Coordinator

Other projects

RefTitleFunding OrganismUnit Role
CTQ2014-52384-RINTELLIGENT APPLICATIONS BASED ON NANOSTRUCTURED FIBERS CONTAINING NATURAL BIOCIDES WITH PHARMACOKINETIC CONTROL OF THEIR RELEASEMinisterio de Economia y CompetitividadParticipant
CTQ2013-49068-C2-1-RMICROSYSTEMS BASED ON NANOSTRUCTURES WITH SPECIFIC PROPERTIES OF ADSORPTION AND SUPERFICIAL PLASMON, FOR DETECTION OF HIDDEN EXPLOSIVES AND AGENTS OF CHEMICAL WAR.Ministerio de Economia y CompetitividadParticipant
TARMACTARMAC. New tools for the diagnosis and treatment of respiratory infectious diseases: pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistenceMinisterio de Economia y competitividadParticipant
TARMAC/IQMA-UDM-UPVpH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistenceCIBER-BBN-CIBERES-SEPARParticipant
H2020-MSCA-ITN-2016/H2020-MSCA-ITN-2016European Training Network for Continuous Sonication and Microwave Reactors.Unión EuropeaParticipant
H2020-SPIRE-2014-2015 ADREM / Adaptable Reactors for Resource- and Energy-Efficient Methane ValorisationUnión EuropeaParticipant
I-2012/023Development of a microfluidic platform to produce nanomaterials and assessment on new nanotechnology applicationsUnión EuropeaParticipant
CTQ2016-77147-RNEW STRATEGIES FOR CO2 CONVERSION USING CATALYSTS UNDER ELECTROMAGNETIC RADIATION.MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDADParticipant
CTQ2016-79419-RADVANCED ADSORPTION TECHNOLOGIES, SERS DETECTION AND CATALYSIS FOR CHEMICAL WARMINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDADParticipant
NANOHEDONISMA photo-triggered on-demand drug delivery system for chronic painEuropean Research CouncilParticipant
I-2011/004HECTOR- MICROWAVE-ASSISTED MICROREACTORS: DEVELOPMENT OF A HIGHLY EFFICIENT GAS PHASE CONTACTOR WITH DIRECT CATAYST HEATINGUnión EuropeaParticipant
FIS PI15/01118Towards an advanced therapy of bone regeneration: tissue intermediates activated by infrared energy for the controlled expression of osteogenic and angiogenic factorsINSTITUTO DE SALUD CARLOS IIIOthers
AMBITAnimal Model of Bone Regeneration Induced by Tissue Intermediates Responsive to Near-Infrared LightRoche FarmaParticipant

Publications

2016

  • Sebastian V., Smith C.D., Jensen K.F.. Shape-controlled continuous synthesis of metal nanostructures. Nanoscale. 2016;8(14):7534-7543.

News U9

09 Nov

Jesús Santamaría new Corresponding Academician of the Royal Canary Academy of Sciences

Jesús Marcos Santamaría Ramiro, Scientific Director of NANBIOSIS Unit 9 Synthesis of Nanoparticles Professor of Chemical Engineering at the University of Zaragoza and Deputy Director of the University Institute of Nanoscience of Aragon has been appointed new Corresponding Academician of the Royal Canary Academy of Sciences. Reception of the new Corresponding Academician took place last November 7th at the Hall of the Canary Islands Advisory Council in La Laguna the entry speech of the new Corresponding Academician was tittled “Heterogeneous Catalysis 4.0: Opportunities for catalysts when they leave the reactor”[...]

03 Nov

New inside backcober by researchers of NANBIOSIS U9

Researchers of NANBIOSIS U9 Synthesis of Nanoparticles Unit Ignacio Julian, José L. Hueso, Reyes Mallada and Jesús Santamaría, are co-authors of an article with inside backcover recently published by the scientific magazine Catalysis, Science and Tecnology. The synthesis of the materials has been performed at the Platform of Production of Biomaterials and Nanoparticles of the NANBIOSIS ICTS, more specifically at the Nanoparticle Synthesis Unit 9 of the CIBER in BioEngineering, Biomaterials & Nanomedicine (CIBER-BBN) Article: Polyoxometalates as alternative Mo precursors for methane dehydroaromatization on Mo/ZSM-5 and Mo/MCM-22 catalysts. Julián I, Hueso J.L, Lara N, Solé-Daurá A, Poblet J,M, Mitchell S.G, MalladaR, Santamaría J.Catal. Sci.[...]

30 Oct

Killing cancer from starvation or by toxicity with Trojan horses.

Jesús Santamaría, who leads the NFP research group of CIBER-BBN and the Institute of Nanoscience of Aragon (INA), at the University of Zaragoza, in an interview on October 29 to Aragon TV, talks about the problems in the fight against cancer and explains in a very didactic way, the solutions that are being approached from his research group, in collaboration with other groups. It would consists, basically, in reducing the tumor from inside the tumor cells. Prof. Santamaria has been granted funding twice from the European Research Council (ERC) Advanced Grant program for catalysis-related projects, the last one with two[...]

16 Aug

The University of Zaragoza, in the elite of the 500 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, once again places the University of Zaragoza among the elite of the 500 best universities in the world. This indicator organizes up to 20,000 university centers worldwide. Among the keys that have been able to positively influence the results of the research, according to the Vice Chancellor for Prospect, Sustainability and Infrastructure of the University of Zaragoza, Francisco Serón, are the increase in public campus funding for four years as well as the quality of their Scientists. The University of Zaragoza houses[...]

25 Jun

Do you want to join the nanotechnology revolution?

From the NFP research group of CIBER-BBN and INA, led by Jesus Santamaria, that coordinates NANBIOSIS U9 Synthesis of Nanoparticles Unit, and through the SAMCA Nanotechnology Chair, the call for grants has been launched: Nanotechnological Bonds For more information: http://capsulasdenanotecnologia.es/bonos-nanotec/[...]

13 Mar

“Matrioskas” of nanoparticles, a new therapeutic approach against tuberculosis

Researchers of NANBIOSIS U9 Synthesis of Nanoparticles Unit Manuel Arruebo and Víctor Sebastián have participated in a research published in the journal Nanomedicine Tuberculosis is an infectious disease that poses a serious public health problem and, according to WHO data, 10.4 million people became ill with tuberculosis and 1.7 million died in 2016. Therefore, advance in the development of new tools for diagnosis and treatment is essential and the use of nanoparticles could open a new horizon to deal with the infections caused by Mycobacterium tuberculosis. In this line, researchers from the CIBER at the University of Zaragoza, and at[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

09 Oct

Researchers of NANBIOSIS U9 awarded for a work on scaffolds for dental regeneration

Researchers Manuel Arruebo and Víctor Sebastián, from the CIBER-BBN group led by Jesús Santamaría (NFP) at the University of Zaragoza, that coordinates NANBIOSIS Unit 9 Synthesis of Nanoparticles, have received the second prize of the Resomer Awards granted by the company Evonik, a international recognition to competitiviness. Their work “Promoting bioengineered tooth innervation using nanostructured and hybrid scaffolds”, has been published in the journal Acta Biomaterialia 50 (2017) 493-501. In this work, the researchers of the CIBER-BBN manufactured biodegradable materials such as scaffolds to promote dental regeneration. These scaffolds contained an immunosuppressive drug that, in addition to avoiding rejection after implantation,[...]

Tags: